"Czech Republic Pharmaceuticals & Healthcare Report Q1 2015" Now Available at Fast Market Research
Czech Republic's disease and drug consumption profile illustrates a considerable gap between it and Western Europe, suggesting that the population's demand for high-value innovative medicines will continue until convergence. The healthcare spending of the Czech population remains superior to that of the less-developed markets of Eastern and South Eastern Europe, demonstrating that demand in these regions will be even higher. However, the government's short-term ability to provide these medicines remains a key challenge.
View full press release